Alofisel
Takeda writes off $770M after failures of Alofisel and Exkivity
Anika Sharma
Takeda, the Japanese pharmaceutical company, is grappling with significant impairment charges totaling 115.8 billion Japanese yen ($770 million) in its ...
Takeda’s Alofisel fails to meet primary endpoint in phase 3 trial for Crohn’s disease complication
Anika Sharma
Takeda, following its decision to remove an early-stage Crohn’s disease candidate from its pipeline earlier this year, is now contending ...
